EyeBiotech Ltd.
Ranibizumab
Diabetic Macular Edema (DME)
Countdown
86days
Phase 3 readout · ~ Sep 30, 2026 estimated
What's at stake
Phase 3 trial results for Ranibizumab in Diabetic Macular Edema (DME) are due ~ Sep 30, 2026. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· ClinicalTrials.gov
verified 13h ago
“CT.gov NCT06571045: Phase 3 trial, sponsor EyeBiotech Ltd., drug Ranibizumab. Primary completion date 2026-09-30 (estimated).”